Search Results for "Dvt Anticoagulation And Bleeding"
Original Source: Anticoagulation for venous thromboembolism. What if they bleed?
Acute venous thromboembolism (VTE) is treated with parenteral administration of heparin or derivatives, in conjunction with oral vitamin K antagonists (VKAs) to reach and maintain INR values between 2.0 and 3.0 for at least 3 months; the duration of a further period of treatment for secondary prevention of recurrences is still matter of debate. If bleeding occurs during treatment the decision will be based on: a) type of bleeding (major or minor), and b) thrombotic risk if anticoagulation is withheld (chara...
Matching Channels
Matching News
Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk
For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin...
New Design Mechanical Heart Valve Requires Low-Dose Anticoagulation Therapy, Decreases Bleeding Risk
For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin...
FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding
The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major b...
FDA Approves Kcentra for the Reversal of Anticoagulation In Adults
The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major b...
FDA approves CSL's Kcentra and accepts Octapharma Octaplex BLA for reversal of anticoagulation
The US Food and Drug Administration has approved Kcentra (prothrombin complex concentrate, human) from Germany-based CSL Behring, a subsidiary of Australia's CSL Ltd (ASX: CSL), for the urgent reversa...
FDA Okays Kcentra to Reverse Anticoagulation, Stop Bleeding
The plasma-derived product, like plasma itself, can stop major bleeding, but it can be deployed more quickly because it does not require blood group typing or thawing. FDA Approvals
Kcentra gets FDA approval for adults with acute major bleeding
The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleedin...
FDA Approves Kcentra For Acute Bleeding
A drug for acute major bleeding, called Kcentra (Prothrombin Complex Concentrate, Human) has just been approved by the U.S. Food and Drug Administration. Kcentra, manufactured by CSL Behring, Marburg...
Matching PubMed Articles
Perioperative management of chronic anticoagulation in orthopaedic surgery.
The orthopaedic patient on chronic anticoagulation therapy is at risk of thromboembolism and hemorrhage in the perioperative period. To establish the most effective anticoagulation regimen, patients s...
Risk of falls and major bleeds in patients on oral anticoagulation therapy.
The risk of falls is the most commonly cited reason for not providing oral anticoagulation, although the risk of bleeding associated with falls on oral anticoagulants is still debated. We aimed to eva...
The benefits of prophylactic anticoagulation or antiplatelet therapy for patients undergoing extracardiac conduit (ECC) Fontan procedure still are a matter of debate. Through a systematic review and m...
PURPOSE: Patients on chronic oral anticoagulation can be challenging to manage in the perioperative period. METHODS: Review of patients on warfarin undergoing elective abdominal colon and rectal opera...
Introduction: Currently used anticoagulants such as unfractionated heparin, low-molecular-weight heparin and vitamin K antagonists, have several drawbacks, mostly related to safety. In this review, we...
